Abstract
Introduction
This study compared pathological characteristics and patterns of disease recurrence for patients with pT1 esophageal adenocarcinoma treated with either laparoscopic transhiatal esophagectomy or open esophagectomy.
Methods
From January 2000-December 2006, 44 patients had pT1 esophageal adenocarcinoma after esophagectomy. No patients had neoadjuvant treatment. Twenty-four patients had an Ivor Lewis operation, 4 had an open transhiatal and 16 had a laparoscopic transhiatal operation.
Results
There were 37 men. The median age was 64 years (range 35–80 years). Median lymph node yield was 19 (10–51) after an Ivor Lewis operation, 16 (3–28) after an open transhiatal operation and 15 (4–41) after a laparoscopic transhiatal operation. There were two in-hospital deaths (5%), both following open Ivor Lewis operation. All patients in the laparoscopic group had N0 disease; none received adjuvant treatment. Two patients (7%) in the open group had N1 disease, of whom one patient received adjuvant chemotherapy. Eleven patients had submucosal invasion. Alive patients had median follow-up of 36 months (range 5–87 months). One patient in the laparoscopic group had recurrence at 22 months. This patient had poorly differentiated N0 disease which was limited to the mucosa and died at 24 months. Two patients in the open group developed recurrence, at 6 months (N0 disease with submucosal invasion) and 8 months (N1 disease with submucosal invasion) and died at 7 and 14 months, respectively. Both patients had poorly differentiated tumours. The second patient with N1 disease is alive and well at 14 months. Estimated survival (Kaplan–Meier) at 3 years was 93%.
Conclusions
As compared with open transthoracic esophagectomy, there is no oncological detriment in the treatment of pT1 esophageal adenocarcinoma by laparoscopic transhiatal esophagectomy. The incidence of recurrence is small (7%) but can occur even in patients with tumour limited to the mucosa or N0 disease.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Portale G, Hagen JA, Peters JH, Chan LS, DeMeester SR, Gandamihardja TA, DeMeester TR (2006) Modern 5-year survival of resectable esophageal adenocarcinoma: single institution experience with 263 patients. J Am Coll Surg 202(4):588–596
van Sandick JW, van Lanschot JJ, Kuiken BW, Tytgat GN, Offerhaus GJ, Obertop H (1998) Impact of endoscopic biopsy surveillance of Barrett’s oesophagus on pathological stage and clinical outcome of Barrett’s carcinoma. Gut 43(2):216–222
Froelicher P, Miller G (1986) The European experience with esophageal cancer limited to the mucosa and submucosa. Gastrointest Endosc 32:88–90
Sagar PM, Gauperaa T, Sue-Ling H, McMahon MJ, Johnston D (1994) An audit of the treatment of cancer of the oesophagus. Gut 35(7):941–945
Nabeya K, Hanaoka T, Li S, Nyumura T (1993) What is the ideal treatment for early esophageal cancer? Endoscopy 25(Suppl):670–671
Kodama M, Kakegawa T (1998) Treatment of superficial cancer of the esophagus: a summary of responses to a questionnaire on superficial cancer of the esophagus in Japan. Surgery 123:432–439
Holscher AH, Bollschweiler E, Schneider PM, Siewert JR (1995) Prognosis of early esophageal cancer: comparison between adeno- and squamous cell carcinoma. Cancer 76:178–186
Sarela AI, Tolan DJ, Harris K, Dexter SP, Sue-Ling HM (2008) Anastomotic leakage after esophagectomy for cancer: a mortality-free experience. J Am Coll Surg 206(3):516–523
Gore RM, Mehta UK, Berlin JW, Rao V, Newmark GM (2006) Upper gastrointestinal tumours: diagnosis and staging. Cancer Imaging 29(6):213–217
Connors RC, Reuben BC, Neumayer LA, Bull DA (2007) Comparing outcomes after transthoracic and transhiatal esophagectomy: a 5-year prospective cohort of 17, 395 patients. J Am Coll Surg 205(6):735–740
Omloo JM, Lagarde SM, Hulscher JB, Reitsma JB, Fockens P, van Dekken H, Ten Kate FJ, Obertop H, Tilanus HW, van Lanschot JJ (2007) Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the mid/distal esophagus: five-year survival of a randomized clinical trial. Ann Surg 246(6):992–1000
Stein HJ, Feith M, Mueller J, Werner M, Siewert JR (2000) Limited resection for early adenocarcinoma in Barrett’s esophagus. Ann Surg 232(6):733–742
Benzoni E, Terrosu G, Bresadola V, Uzzau A, Intini S, Noce L, Cedolini C, Bresadola F, De Anna D (2007) A comparative study of the transhiatal laparoscopic approach versus laparoscopic gastric mobilisation and right open transthoracic esophagectomy for esophageal cancer management. J Gastrointestin Liver Dis 16(4):395–401
Braghetto I, Csendes A, Cardemil G, Burdiles P, Korn O, Valladares H (2006) Open transthoracic or transhiatal esophagectomy versus minimally invasive esophagectomy in terms of morbidity, mortality and survival. Surg Endosc 20(11):1681–1686
Nguyen NT, Roberts P, Follette DM, Rivers R, Wolfe BM (2003) Thoracoscopic and laparoscopic esophagectomy for benign and malignant disease: lessons learned from 46 consecutive procedures. J Am Coll Surg 197(6):902–913
Cadière GB, Torres R, Dapri G (2006) Thoracoscopic and laparoscopic oesophagectomy improves the quality of extended lymphadenectomy. Surg Endosc 20(8):1308–1309
Sandick JW, Lanschot JJB, Kate FJW, Offerhaus GJA, Fockens P, Tytgat GN, Obertop H (2000) Pathology of early invasive adenocarcinoma of the esophagus or esophagogastric junction. Cancer 88:2429–2437
Rice TW, Blackstone EH, Goldblum JR, DeCamp MM, Murthy SC, Falk GW, Ormsby AH, Rybicki A, Richter JE, Adelstein DJ (2001) Superficial adenocarcinoma of the esophagus. J Thorac Cardiovasc Surg 122:1077–1086
Liu L, Hofstetter WL, Rashid A, Swisher SG, Correa AM, Ajani JA, Hamilton SR, Wu TT (2005) Significance of the depth of tumor invasion and lymph node metastasis in superficially invasive (T1) esophageal adenocarcinoma. Am J Surg Pathol 29(8):1079–1085
Westerterp M, Koppert LB, Buskens CJ, Tilanus HW, ten Kate FJ, Bergman JJ, Siersema PD, van Dekken H, van Lanschot JJ (2005) Outcome of surgical treatment for early adenocarcinoma of the esophagus or gastro-esophageal junction. Virchows Arch 446(5):497–504
Sarela AI, Scott N, Verbeke CS, Wyatt JI, Dexter SP, Sue-Ling HM, Guillou PJ (2005) Diagnostic variation and outcome for high-grade gastric epithelial dysplasia. Arch Surg 140(7):644–649
Rizk N, Venkatraman E, Park B, Flores R, Bains MS, Rusch V (2006) American Joint Committee on Cancer staging system. The prognostic importance of the number of involved lymph nodes in esophageal cancer: implications for revisions of the American Joint Committee on Cancer staging system. J Thorac Cardiovasc Surg 132(6):1374–1381
Tachibana M, Kinugasa S, Shibakita M, Tonomoto Y, Hattori S, Hyakudomi R, Yoshimura H, Dhar DK, Nagasue N (2006) Surgical treatment of superficial esophageal cancer. Langenbecks Arch Surg 391(4):304–321
Ruol A, Parenti A, Zaninotto G, Merigliano S, Costantini M, Cagol M, Alfieri R, Bonavina L, Peracchia A, Ancona E (2000) Intestinal metaplasia is the probable common precursor of adenocarcinoma in Barrett esophagus and adenocarcinoma of the gastric cardia. Cancer 88(11):2520–2528
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Saha, A.K., Sutton, C.D., Sue-Ling, H. et al. Comparison of oncological outcomes after laparoscopic transhiatal and open esophagectomy for T1 esophageal adenocarcinoma. Surg Endosc 23, 119–124 (2009). https://doi.org/10.1007/s00464-008-0065-z
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00464-008-0065-z